Wells Fargo & Company Coherus Bio Sciences, Inc. Transaction History

Wells Fargo & Company

  • $433 Billion
  • Q4 2024

A detailed history of Wells Fargo & Company transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 61,830 shares of CHRS stock, worth $72,959. This represents 0.0% of its overall portfolio holdings.

Number of Shares
61,830
Previous 46,693 32.42%
Holding current value
$72,959
Previous $48,000 77.08%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 12, 2025
BUY
$0.67 - $1.71 $10,141 - $25,884
15,137 Added 32.42%
61,830 $85,000
Q3 2024

Nov 13, 2024
BUY
$0.99 - $1.8 $1,736 - $3,157
1,754 Added 3.9%
46,693 $48,000
Q2 2024

Aug 13, 2024
BUY
$1.58 - $2.51 $15,308 - $24,319
9,689 Added 27.49%
44,939 $77,000
Q1 2024

May 10, 2024
BUY
$2.02 - $3.14 $12,410 - $19,292
6,144 Added 21.11%
35,250 $84,000
Q4 2023

Feb 09, 2024
SELL
$1.59 - $3.85 $243,840 - $590,432
-153,359 Reduced 84.05%
29,106 $96,000
Q3 2023

Nov 13, 2023
BUY
$3.74 - $5.45 $547,162 - $797,335
146,300 Added 404.53%
182,465 $682,000
Q2 2023

Aug 15, 2023
SELL
$3.79 - $8.3 $186,888 - $409,281
-49,311 Reduced 57.69%
36,165 $154,000
Q1 2023

May 12, 2023
BUY
$5.89 - $10.52 $470,546 - $840,432
79,889 Added 1429.91%
85,476 $584,000
Q4 2022

Feb 13, 2023
SELL
$5.69 - $10.07 $22,606 - $40,008
-3,973 Reduced 41.56%
5,587 $44,000
Q3 2022

Nov 14, 2022
SELL
$7.17 - $13.87 $8,245 - $15,950
-1,150 Reduced 10.74%
9,560 $92,000
Q2 2022

Aug 12, 2022
SELL
$5.86 - $13.23 $168,996 - $381,539
-28,839 Reduced 72.92%
10,710 $78,000
Q1 2022

May 16, 2022
SELL
$10.92 - $16.41 $231,099 - $347,284
-21,163 Reduced 34.86%
39,549 $512,000
Q4 2021

Feb 14, 2022
SELL
$15.81 - $18.99 $1.27 Million - $1.52 Million
-80,117 Reduced 56.89%
60,712 $969,000
Q3 2021

Nov 15, 2021
SELL
$12.68 - $17.79 $1.37 Million - $1.92 Million
-107,706 Reduced 43.34%
140,829 $2.26 Million
Q2 2021

Aug 16, 2021
SELL
$12.95 - $15.41 $18,194 - $21,651
-1,405 Reduced 0.56%
248,535 $3.44 Million
Q1 2021

May 13, 2021
SELL
$14.42 - $21.39 $1.04 Million - $1.54 Million
-71,825 Reduced 22.32%
249,940 $3.65 Million
Q4 2020

Feb 09, 2021
SELL
$16.56 - $18.94 $1.34 Million - $1.53 Million
-81,028 Reduced 20.12%
321,765 $5.59 Million
Q3 2020

Nov 05, 2020
BUY
$17.41 - $19.89 $178,452 - $203,872
10,250 Added 2.61%
402,793 $7.39 Million
Q2 2020

Aug 13, 2020
BUY
$14.43 - $19.16 $162,395 - $215,626
11,254 Added 2.95%
392,543 $7.01 Million
Q1 2020

May 14, 2020
BUY
$11.67 - $22.53 $4.45 Million - $8.59 Million
381,289 New
381,289 $6.18 Million

Others Institutions Holding CHRS

# of Institutions
133
Shares Held
70M
Call Options Held
1.16M
Put Options Held
39.5K
View Full List

About Coherus BioSciences, Inc.

CHRS Quotes by TradingView
  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $91.7M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email